Introduction
============

Neuroradiology with cranial magnetic resonance imaging (MRI) using fluid-attenuated inversion recovery (FLAIR) and T1-weighted sequences prior to and following contrast injection combined with diffusion-weighted imaging (DWI) is the method of choice for the diagnosis and follow-up of primary central nervous system (CNS) lymphoma (PCNSL) ([@b1-ol-0-0-8839]). The typical features of PCNSL are intra-axial homogenous single or multiple contrast-enhancing lesions with markedly restricted diffusion that are in contact with a cerebrospinal fluid (CSF) surface ([@b2-ol-0-0-8839]).

Lymphomatosis cerebri is a rare form of PCNSL characterized by diffuse lymphomatous parenchymal infiltration without evidence of cohesive masses or parenchymal architectural distortion ([@b3-ol-0-0-8839]). The distinguishing neuroradiological features of lymphomatosis cerebri have not yet been established in detail, as the literature contains only case reports and small series reporting imaging findings. In brain MRI studies, lymphomatosis cerebri can be mistaken for a variety of diffuse infiltrative brain tumors or leukoencephalopathy ([@b2-ol-0-0-8839]).

The present study first describes a case involving a 56-year-old immunocompetent woman who presented with diffuse infiltrating lesions in the brain parenchyma with perivascular curvilinear enhancement on initial MRI and multiple nodules on the later follow-up computed tomography (CT) scans. The current study also presents the results of a systematic review of the clinical and neuroradiological features of lymphomatosis cerebri. Using strict inclusion criteria, a literature search was performed on the data recorded between January 1996 and December 2016. To the best of our knowledge, this study provides the largest systematic review of neuroradiological features for lymphomatosis cerebri to date, and the present case is the first to be reported with perivascular curvilinear enhancement and subsequent multiple nodules.

Materials and methods
=====================

### Case report

Written informed consent was obtained from the daughter of the patient for publication of this case report and any accompanying data. A 56-year-old immunocompetent woman presented Guangdong Provincial Corps Hospital of Chinese People\'s Armed Police Forces (Guangzhou, China) with acute onset of headache, confusion and inability to relevantly answer questions on February 25, 2015. Blurred vision had occurred 20 days prior to admission. Personality and behavior changes had appeared 10 days prior to admission. The neurological examination showed fluctuating spatiotemporal disorientation with dyscalculia, a weak voice and moderate bradykinesia. Non-contrast brain CT (LightSpeed VCT XT CT 64-row helical CT scanner; GE Healthcare, Chicago, IL, USA) performed on February 25, 2015, showed abnormal low density results in the right parietal white matter, external capsule and thalamus ([Fig. 1](#f1-ol-0-0-8839){ref-type="fig"}). On the initial brain MRI (MAGNETOM SKyra 3T MRI scanner; Siemens Healthineers, Erlangen, Germany) performed following admission on February 26, 2015, the T2-weighted images (T~2~WI) \[repetition time (TR), 6,000 msec; echo time (TE), 99 msec; slice thickness, 5 mm; distance factor, 30%; voxel size, 0.3×0.3×5.0 mm; field of view (FOV), 22×22 cm\] and FLAIR images (TR, 9,000 msec; TE, 85 msec; slice thickness, 5 mm; distance. factor, 30%; voxel size, 0.4×0.4×5.0 mm; FOV, 22×22 cm) showed asymmetric and diffuse white-matter hyperintensities involving bilateral paraventricular white matter, bilateral temporal lobes, the left occipital lobe, the medial prefrontal cortex, bilateral basal ganglia, the thalamus and the midbrain, as well as a slight mass effect on the posterior horn of the left lateral ventricle ([Fig. 2](#f2-ol-0-0-8839){ref-type="fig"}). DWI (TR, 4,500 msec; TE, 64 msec; slice thickness, 5 mm; dist. factor, 30%; voxel size, 1.4×1.4×5.0 mm; FOV, 22×22 cm; b value, 1,000 sec/mm^2^) showed mild hyperintense signals, corresponding with T2/FLAIR hyperintensities ([Fig. 2](#f2-ol-0-0-8839){ref-type="fig"}). Apparent diffusion coefficient (ADC) maps showed that the areas of increased diffusion signal represented both shine-through artifacts and mild diffusion restriction ([Fig. 2C](#f2-ol-0-0-8839){ref-type="fig"}). Subsequent to the bolus intravenous injection of 10 ml gadodiamide (Omniscan^®^; GE Healthcare), T~1~-weighted images (T~1~WI) (TR, 250 msec; TE, 2.49 msec; slice thickness, 5 mm; dist. factor, 30%; voxel size, 0.7×0.7×5.0 mm; FOV, 22×22 cm) showed that asymmetric perivascular curvilinear enhancement perpendicular to the lateral ventricle was present in the bilateral cerebral white matter, and that eppendymal enhancement around the left ventricle and additional more patchy enhancement in the bilateral cerebral white matter were present ([Fig. 2](#f2-ol-0-0-8839){ref-type="fig"}). CSF pressure was 160 mmH~2~O during lumbar puncture. CSF anlysis revealed 0.46 g/l protein (normal range, 0.15--0.45 g/l), 3.8 mmol/l glucose (normal range, 3.3--4.4 mmol/l) and 119.8 mmol/l chloride (normal range, 122--128 mmol/l). No bacteria were detected via gram stain and culture in the CSF. Cytological analysis of the CSF was negative for malignancy, and no oligoclonal bands could be found. Autoimmune and viral serologies were negative.

The patient was initially diagnosed with acute disseminated encephalomyelitis and treated with 500 mg methylprednisolone via intravenous infusion once a day for 10 days. Following an improved clinical situation, the patient was discharged on March 15, 2015.

The patient gradually developed gait disturbance, personality changes and dementia beginning on April 10, 2015. On April 22, 2015, a repeat MRI with the aforementioned sequence parameters showed diffuse and asymmetrical pathological signal hyperintensities on T2/FLAIR images, a slightly hyperintense signal on DWI and asymmetric perivascular curvilinear enhancement on T~1~WI with gadolinium that had expanded compared with that in the initial MRI ([Fig. 2](#f2-ol-0-0-8839){ref-type="fig"}). Whole-body fluorodeoxyglucose positron emission tomography/CT (FDG-PET/CT) scans (Biograph^™^ mCT PET/CT Scanner; Siemens Healthineers) were also acquired on April 23, 2015 ([Fig. 3](#f3-ol-0-0-8839){ref-type="fig"}). No primary FDG-avid malignancy was identified. Brain FDG-PET was markedly abnormal, with increased uptake in the bilateral frontal, parietal, occipital and temporal lobes, basal ganglia, midbrain, cerebellum and cervical cord.

### Immunohistochemistry

A stereotactic brain biopsy of the left frontal lobe was performed on May 8, 2015. The tissue specimens were fixed in 10% neutral buffered formalin solution for 24 h at room temperature, followed by paraffin embedding. Sections with a thickness of 4 ìm were cut and mounted on glass slides for hematoxylin-eosin (H&E) staining performed by a 3 min incubation in hematoxylin followed by a 30 sec incubation in eosin at room temperature. For immunohistological (IHC) staining, 4 ìm paraffin tissue sections were mounted on silanized glass slides using chrome-alum gelatin as adhesive. IHC staining was performed by the Streptavidin-Biotin-Complex (SABC) method according to the Sixth Edition of Dako\'s Educational Guidebook to IHC Staining Methods ([@b4-ol-0-0-8839]). Sections were deparaffinized in xylene (2×10 min) and rehydrated through an alcohol gradient: 100% ethanol (2×10 min), 95% ethanol (1×8 min), 80% ethanol (1×5 min), and 70% ethanol (1×5 min) followed by 1×10 min in ddH~2~O. Then nonspecific background staining was blocked with Background Sniper (BS966M, Biocare Medical, LLC, Paheco, CA, USA), 3% bovine serum albumin (BSA; Sigma-Aldrich; Merck KGaA, Darmstadt, Germay) in phosphate-buffered saline (PBS) and 5% normal goat-serum solution (OriGene Technologies, Inc., Beijing, China) for 30 min at room temperature. Slides were incubated overnight at 4°C with primary antibodies in 3% BSA-PBS. The following antibodies were applied as primary antibodies at a 1:1,000 dilution in Bond primary antibody diluent (cat. no. AR9590; Leica Biosystems, Newcastle, UK), Anti-CK (cat. no. 103228N; Ascend Biotechnology Co., Ltd., Guangzhou, China), anti-CD3 (cat. no. 18379501; OriGene Technologies, Inc.), anti-CD20 (cat. no. 104048N; Ascend Biotechnology Co., Ltd., Guangzhou, China), anti-GFAP (cat. no. 112147N; Ascend Biotechnology Co., Ltd.), anti-S-100 (cat. no. 112117N; Ascend Biotechnology Co., Ltd.), anti-cyclin D1 (cat. no. 17650111; OriGene Technologies, Inc.), anti-CD79a (cat. no. 111027N; Ascend Biotechnology Co., Ltd.), anti-PAX-5 (cat. no. 17600412; OriGene Technologies, Inc.), anti-Bcl-2 (cat. no. 17312610; OriGene Technologies, Inc.), anti-Bcl-6 (cat. no. 18343803; OriGene Technologies, Inc.), anti-CD21 (cat. no. 17660809; OriGene Technologies, Inc.), anti-Ki-67 (cat. no. 111167N; Ascend Biotechnology Co., Ltd.), anti-CD10 (cat. no. 20045299; Dako; Agilent Technologies GmbH, Waldbronn, Germany), and anti-Mum-1 (cat. no. 102288N; Ascend Biotechnology Co., Ltd.). After rinsing 5 times with 0.05% Brij-35 in PBS for 1 min, slides were then incubated with the horseradish peroxidase conjugated Goat anti-Human IgG secondary antibody at 1:1,000 dilution (cat. no. 20047066; Dako; Agilent Technologies GmbH) for 1 h at room temperature. The entire section was systematically examined under high power fields (×400 magnification) in Leica DMLA light microscope (Leica Microsystems, Wetzlar, Germany). The criteria for positive staining was defined as \>80% positive staining cells for the Ki-67 and Mum-1 antibodies, and ≥30% for the other antibodies including CD10, CD20, CD79a and Bcl-6 antibodies. The pathological diagnosis was diffuse large B-cell lymphoma of non-germinal center B-cell type (non-GCB), IHC exhibited strong staining for B-cell markers CD-20, CD-79a and Ki-67, as well as negative for CD-10 and Bcl-6; however, was positive for MUM-1 ([Fig. 4](#f4-ol-0-0-8839){ref-type="fig"}).

### Treatment regimen

High-dose methotrexate and rituximab were administered as follows: 8 g/m^2^ methotrexate (day 1) and 375 mg/m^2^ rituximab (day 3), repeated every 14 days. Following three courses of chemotherapy, severe myelosuppression developed. On July 4, 2015, the patient suddenly collapsed and began comatose, and a non-contrast brain CT showed extension of the pathological hypodensities and multiple circular nodules in the white matter lesions of the cerebrum and cerebellum ([Fig. 1](#f1-ol-0-0-8839){ref-type="fig"}). The patient succumbed to severe pulmonary infection and serious bleeding resulting from myelosuppression on September 2, 2015.

### Methods

The PubMed database was searched on December 2016 using the following terms: 'Lymphomatosis cerebri', and ('PCNSL' or 'brain lymphoma') and ('non-enhancing' or 'diffuse' or 'diffuse infiltrative'). Cited articles of each relevant study were also reviewed for possible relevant articles. Only articles in the English language literature were evaluated.

The definition of lymphomatosis cerebri in the present systematic review was that the T2/FLAIR abnormal hyperintensity involved at least three cerebral lobes or three anatomical regions of the CNS in accordance with the description of gliomatosis cerebri in the 2007 World Health Organization classification of tumors of the CNS ([@b5-ol-0-0-8839]), but also that the non-enhancing lesions or the lesions without nodular or mass enhancement were identified on initial MR images. According to information from full-text articles, the following criteria were used to define inclusion into this systematic literature review: i) The full-text article included at least a T~2~WI or FLAIR image, and a contrast-enhanced T~1~WI; ii) the lesions involved at least three cerebral lobes or anatomical regions of the brain; iii) the lesions showed non-enhancement or non-nodular/non-mass-like enhancement on the initial MRI; and iv) the lesions were pathologically confirmed as PCNSL. The exclusion criteria were as follows: i) Concurrent systemic lymphoma; ii) intravascular CNS lymphoma; iii) inconclusive histological data; iv) failure to provide any MR image in the full-text article; v) only providing CT images in the full-text article; vi) prior surgery, radiotherapy, chemotherapy or corticosteroid therapy; and vii) a non-English article. Any case report that did not meet this definition and these criteria was excluded from the present systematic review, even if the author referred to the condition as lymphomatosis cerebri ([@b6-ol-0-0-8839]--[@b11-ol-0-0-8839]). The present study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines ([@b12-ol-0-0-8839]).

The collected data included the clinical data, pathological results and imaging findings. Neuroradiological techniques analyzed included CT, MRI \[T~1~WI, T~2~WI, FLAIR, T~1~WI with gadolinium contrast enhancement, DWI, diffusion tensor imaging (DTI) and magnetic resonance spectroscopy (MRS)\], single-photon emission computed tomography (SPECT) and PET (if any). The lesion location, distribution, morphology, density, contrast enhancement and follow-up imaging were recorded.

Results
=======

### Search results

The PRISMA-style flow diagram of identifying literature for this systematic review is outlined in [Fig. 5](#f5-ol-0-0-8839){ref-type="fig"}. PubMed database searches and reference articles searched by manual methods identified 73 articles. A total of 34 articles were excluded that did not meet the review inclusion criteria. Furthermore, 5 case reports from 1 case series were excluded due to a lack of any MR image. Thus, 39 relevant publications were included in the present systematic review for a total of 44 previously reported cases ([@b13-ol-0-0-8839]--[@b51-ol-0-0-8839]). All publications in this review were case studies without controls, and their publication spanned between January 1996 and December 2016. With the addition of the present new case, the total study cohort was 45 cases of lymphomatosis cerebri. The clinical and neuroradiological features in these 45 cases of lymphomatosis cerebri from the systematic review of the literature are summarized in [Tables I](#tI-ol-0-0-8839){ref-type="table"} and [II](#tII-ol-0-0-8839){ref-type="table"}. A list of detailed clinical data and neuroradiological findings collected from all available case reports are shown as 'On-line [Table I](#tI-ol-0-0-8839){ref-type="table"}' and 'On-line [Table II](#tII-ol-0-0-8839){ref-type="table"}' in the online repository Baidu Netdisk (<https://pan.baidu.com/s/1KeHH0w0aBR6vKO_mLb2lPA>).

### Clinical data

The mean age at onset was 57.3 years (range, 28--85 years), including 22 females and 23 males (sex ratio, 1:1.05). A total of 3 patients (6.7%) were immunosuppressed as a result of acquired immunodeficiency syndrome.

The most common symptoms at onset were progressive dementia and cognitive deficit (44.4%), gait ataxia (37.8%), motor deficit (35.6%), memory loss (24.4%), language deficit (24.4%), changes in consciousness (22.2%), personality changes (17.8%), visual problems (11.1%) and sensory deficit (11.1%). Other clinical features included headaches (8.9%), seizures (8.9%), persistent fever (4.4%), nausea or vomiting (2.2%), anorexia (2.2%), hypersomnia (2.2%), fatigue (2.2%) and vertigo (2.2%).

CSF analysis was mentioned in 35 cases. Abnormal results were observed in 30 of these cases (85.7%), including elevated protein in 22 cases, increased cell counts in 12 cases, decreased glucose in 4 cases, lymphocytosis in 1 case and atypical lymphocytes in 1 case ([Table I](#tI-ol-0-0-8839){ref-type="table"}). None of the 35 CSF cytology reports revealed neoplastic lymphocytes.

### Neuroradiology

The most common localization of diffuse and asymmetric abnormal T2 hyperintensity involved the cerebral white matter in at least three cerebral lobes or three anatomical regions of the CNS on initial MRI matter (35 cases, 77.8%). The lesions most commonly affected the deep and periventricular white matter, and predominantly involved white matter regions of the frontal, parietal, occipital and temporal lobes. Subcortical white matter hyperintensity and U-fiber involvement were frequently observed (24 cases, 53.3%; including the present case) ([@b13-ol-0-0-8839]--[@b15-ol-0-0-8839],[@b17-ol-0-0-8839]--[@b19-ol-0-0-8839],[@b22-ol-0-0-8839],[@b25-ol-0-0-8839],[@b26-ol-0-0-8839],[@b29-ol-0-0-8839],[@b32-ol-0-0-8839], [@b34-ol-0-0-8839],[@b36-ol-0-0-8839],[@b38-ol-0-0-8839],[@b40-ol-0-0-8839],[@b42-ol-0-0-8839],[@b43-ol-0-0-8839],[@b45-ol-0-0-8839],[@b48-ol-0-0-8839]--[@b50-ol-0-0-8839]). The lesions involved the corpus callosum in 19 cases (42.2%), the basal ganglia in 15 cases (33.3%), the thalamus in 12 cases (26.7%), the midbrain in 21 cases (46.7%), the pons in 20 cases (44.5%), the medulla in 14 cases (31.1%), the cerebellum in 12 cases (26.6%) and the spinal cord in 5 cases (11.1%) ([Table II](#tII-ol-0-0-8839){ref-type="table"}). Lesions were also observed in the cerebral ([@b20-ol-0-0-8839],[@b28-ol-0-0-8839],[@b41-ol-0-0-8839],[@b43-ol-0-0-8839],[@b50-ol-0-0-8839]) and cerebellar ([@b35-ol-0-0-8839],[@b41-ol-0-0-8839]) cortices, and the cerebellar dentate nuclei ([@b30-ol-0-0-8839]).

The lesion signals on T~2~WI/FLAIR MRI were of high intensity in all cases ([@b13-ol-0-0-8839]--[@b51-ol-0-0-8839]). Non-enhanced T~1~WI as used for 13 patients in the systematic review, of which 6 cases were presented as isointensity and 7 cases were hypointensity. DWI results were described for 14 patients in the present systematic review, of which the lesion signals were isointense in 2 cases ([@b34-ol-0-0-8839],[@b39-ol-0-0-8839]), slightly hyperintense in 11 cases (including the present case) ([@b14-ol-0-0-8839],[@b20-ol-0-0-8839],[@b26-ol-0-0-8839],[@b28-ol-0-0-8839],[@b29-ol-0-0-8839],[@b32-ol-0-0-8839],[@b47-ol-0-0-8839],[@b48-ol-0-0-8839],[@b50-ol-0-0-8839]) and highly hyperintense in 1 case ([@b24-ol-0-0-8839]) compared with the normal gray matter.

A slight mass effect could have been caused by abnormal T2 hyperintensities, and consisted of mild compression of the adjacent ventricle or cistern in 18 cases (including the present case) ([@b17-ol-0-0-8839],[@b18-ol-0-0-8839],[@b20-ol-0-0-8839],[@b22-ol-0-0-8839],[@b23-ol-0-0-8839],[@b28-ol-0-0-8839],[@b30-ol-0-0-8839]--[@b33-ol-0-0-8839],[@b40-ol-0-0-8839],[@b41-ol-0-0-8839],[@b44-ol-0-0-8839]--[@b48-ol-0-0-8839]) or mild sulcal effacement in 5 cases ([@b21-ol-0-0-8839],[@b36-ol-0-0-8839],[@b40-ol-0-0-8839],[@b41-ol-0-0-8839],[@b49-ol-0-0-8839]).

Follow-up CT and/or MRI were mentioned or described for 31 patients. Among them, 10 cases reported 3 brain MRI examinations. In the second MRI, 24 cases showed progression (including the present case) ([@b13-ol-0-0-8839],[@b14-ol-0-0-8839],[@b17-ol-0-0-8839],[@b19-ol-0-0-8839],[@b20-ol-0-0-8839],[@b23-ol-0-0-8839],[@b25-ol-0-0-8839]--[@b27-ol-0-0-8839],[@b30-ol-0-0-8839],[@b33-ol-0-0-8839],[@b35-ol-0-0-8839],[@b37-ol-0-0-8839],[@b38-ol-0-0-8839],[@b41-ol-0-0-8839]--[@b47-ol-0-0-8839],[@b49-ol-0-0-8839]--[@b51-ol-0-0-8839]) ([Figs. 2](#f2-ol-0-0-8839){ref-type="fig"} and [3](#f3-ol-0-0-8839){ref-type="fig"}), 5 cases demonstrated reduction of lesions ([@b28-ol-0-0-8839],[@b32-ol-0-0-8839],[@b36-ol-0-0-8839],[@b37-ol-0-0-8839],[@b39-ol-0-0-8839]) and 2 cases showed no change from the initial scan ([@b26-ol-0-0-8839],[@b34-ol-0-0-8839]). In the third MRI, when reported, 6 cases showed the enlargement of lesions ([@b32-ol-0-0-8839],[@b35-ol-0-0-8839],[@b41-ol-0-0-8839],[@b46-ol-0-0-8839],[@b49-ol-0-0-8839]) and 4 cases revealed the reduction of lesions ([@b23-ol-0-0-8839],[@b26-ol-0-0-8839],[@b30-ol-0-0-8839],[@b34-ol-0-0-8839],[@b37-ol-0-0-8839]). In 16 cases, lesion extension was described as spreading along the corticospinal tract down to the basal ganglia, thalamus, midbrain, pons, medulla oblongata and the left cerebellar hemisphere, even into the spinal cord. Lesions extending through the corpus callosum were also observed ([@b23-ol-0-0-8839],[@b25-ol-0-0-8839],[@b37-ol-0-0-8839],[@b39-ol-0-0-8839],[@b40-ol-0-0-8839]).

Contrast enhancement patterns on MRI could be divided into three forms: i) Non-enhancing (64.4%)([@b13-ol-0-0-8839]--[@b24-ol-0-0-8839],[@b26-ol-0-0-8839]--[@b28-ol-0-0-8839],[@b30-ol-0-0-8839],[@b32-ol-0-0-8839],[@b33-ol-0-0-8839],[@b37-ol-0-0-8839],[@b38-ol-0-0-8839],[@b42-ol-0-0-8839],[@b43-ol-0-0-8839],[@b45-ol-0-0-8839],[@b46-ol-0-0-8839],[@b48-ol-0-0-8839]--[@b51-ol-0-0-8839]) on initial MRI; ii) non-mass-like enhancement (35.6%) on initial MRI; and iii) nodular or mass-like enhancement on follow-up MRI (15.6%). The non-mass-like enhancements on initial MRI were described as subtle (subtle, faint, slight, little and minimal) in 7 cases ([@b34-ol-0-0-8839]--[@b36-ol-0-0-8839],[@b39-ol-0-0-8839],[@b40-ol-0-0-8839],[@b44-ol-0-0-8839],[@b47-ol-0-0-8839]), patchy in 5 cases ([@b22-ol-0-0-8839],[@b29-ol-0-0-8839],[@b32-ol-0-0-8839],[@b48-ol-0-0-8839]) and curvilinear in 4 cases (including the present case) ([@b25-ol-0-0-8839],[@b37-ol-0-0-8839],[@b41-ol-0-0-8839]) ([Fig. 4](#f4-ol-0-0-8839){ref-type="fig"}). In 8 cases with a non-enhancing pattern on initial MRI, follow-up contrast enhancement MRI revealed patchy enhancement in 5 cases ([@b30-ol-0-0-8839],[@b35-ol-0-0-8839],[@b42-ol-0-0-8839],[@b43-ol-0-0-8839],[@b47-ol-0-0-8839]), single nodular enhancement in 1 case ([@b37-ol-0-0-8839]) and mass-like enhancement in 2 cases ([@b35-ol-0-0-8839],[@b50-ol-0-0-8839]). In 1 case that presented as a slight enhancement on initial MRI, mass-like enhancement was subsequently found at 4 months post-admission ([@b35-ol-0-0-8839]). In 4 cases with perivascular curvilinear enhancement on initial MRI, follow-up contrast enhancement MRI revealed patchy enhancement at 5 months post-admission in 1 case, multiple nodular enhancement in 2 cases (including the present case) ([@b25-ol-0-0-8839]) and multiple mass-like enhancement in 1 case ([@b41-ol-0-0-8839]).

MRS findings were described for 4 patients. MRS revealed low N-acetylaspartate levels and high choline peaks in 3 cases ([@b28-ol-0-0-8839],[@b29-ol-0-0-8839],[@b51-ol-0-0-8839]), with low myo-inositol peaks and high lipid peaks in 1 of these cases ([@b51-ol-0-0-8839]). The remaining case showed normal concentration patterns of choline, creatine and N-acetyl aspartate ([@b49-ol-0-0-8839]).

^18^F-FDG PET/CT findings were mentioned in 12 patients, including 4 cases that revealed high uptake (including the present case) ([@b25-ol-0-0-8839],[@b47-ol-0-0-8839],[@b50-ol-0-0-8839]) ([Fig. 4](#f4-ol-0-0-8839){ref-type="fig"}), 3 cases with decreased uptake ([@b31-ol-0-0-8839],[@b36-ol-0-0-8839],[@b47-ol-0-0-8839]) and 5 cases with normal metabolism ([@b23-ol-0-0-8839],[@b26-ol-0-0-8839],[@b29-ol-0-0-8839],[@b34-ol-0-0-8839],[@b43-ol-0-0-8839]).

SPECT findings were described in only 1case, and revealed hyperperfusion ([@b49-ol-0-0-8839]).

### Pathology

All the studies confirmed the diagnosis as lymphomatosis cerebri, by pathological analysis of a brain biopsy in 35 cases (including the present case) ([@b13-ol-0-0-8839],[@b14-ol-0-0-8839],[@b16-ol-0-0-8839],[@b17-ol-0-0-8839],[@b19-ol-0-0-8839]--[@b23-ol-0-0-8839],[@b25-ol-0-0-8839],[@b26-ol-0-0-8839],[@b28-ol-0-0-8839]--[@b30-ol-0-0-8839],[@b32-ol-0-0-8839],[@b34-ol-0-0-8839]--[@b38-ol-0-0-8839],[@b40-ol-0-0-8839]--[@b42-ol-0-0-8839],[@b44-ol-0-0-8839]--[@b50-ol-0-0-8839]) or autopsy in 9 cases ([@b15-ol-0-0-8839],[@b17-ol-0-0-8839],[@b18-ol-0-0-8839],[@b24-ol-0-0-8839],[@b27-ol-0-0-8839],[@b31-ol-0-0-8839],[@b33-ol-0-0-8839],[@b39-ol-0-0-8839],[@b43-ol-0-0-8839]). Only 1 case did not describe the method of pathological sampling ([@b44-ol-0-0-8839]). Tumor cells were distributed throughout the white matter. Single dispersed round neoplastic cells with prominent nuclei were identified under high-power magnification. The typical neoplastic cells were neither cohesive nor formed an ill-defined tumor mass. No necrosis was present. Overall, three patterns of neoplastic cell infiltration were observed in three forms: i) Diffuse scattered infiltration (including the present case) ([@b13-ol-0-0-8839],[@b15-ol-0-0-8839],[@b17-ol-0-0-8839],[@b19-ol-0-0-8839],[@b22-ol-0-0-8839],[@b36-ol-0-0-8839]--[@b38-ol-0-0-8839],[@b40-ol-0-0-8839],[@b41-ol-0-0-8839],[@b47-ol-0-0-8839],[@b48-ol-0-0-8839]) ([Fig. 5](#f5-ol-0-0-8839){ref-type="fig"}); ii) perivascular distribution (including the present case) ([@b15-ol-0-0-8839],[@b16-ol-0-0-8839],[@b18-ol-0-0-8839],[@b29-ol-0-0-8839],[@b33-ol-0-0-8839]--[@b35-ol-0-0-8839],[@b38-ol-0-0-8839],[@b39-ol-0-0-8839],[@b45-ol-0-0-8839],[@b48-ol-0-0-8839],[@b49-ol-0-0-8839]) ([Fig. 5](#f5-ol-0-0-8839){ref-type="fig"}); and iii) massive clusters ([@b27-ol-0-0-8839],[@b32-ol-0-0-8839],[@b42-ol-0-0-8839],[@b45-ol-0-0-8839]).

A total of 40 cases (88.9%) were classified immunohistochemically as B-cell lymphoma and 4 cases (8.9%) were T-cell lymphoma ([@b15-ol-0-0-8839],[@b28-ol-0-0-8839],[@b29-ol-0-0-8839],[@b36-ol-0-0-8839]), while 1 case (2.2%) was not further classified ([@b18-ol-0-0-8839]).

Diffuse large B-cell lymphomas were divided into non-GCB in 5 cases (including the present case) ([@b26-ol-0-0-8839],[@b30-ol-0-0-8839],[@b47-ol-0-0-8839],[@b48-ol-0-0-8839]) ([Fig. 4](#f4-ol-0-0-8839){ref-type="fig"}) and GCB in 1 case ([@b31-ol-0-0-8839]).

### Treatment and prognosis

Overall, 53.3% (24/45) of cases, including the present case, were treated with steroids prior to the diagnosis of lymphomatosis cerebri. Following the stereotactic brain biopsy diagnosing lymphomatosis cerebri, 22.2% (10/45) of cases were treated with radiotherapy. Treatment with chemotherapy occurred in 31.1% (14/45) of cases. Even with aggressive treatment with steroids, radiotherapy and chemotherapy, the median survival time was \<24 months.

Discussion
==========

An understanding of the neuroradiological characteristics of lymphomatosis cerebri has yet to be resolved. The histopathological pattern of diffusely infiltrating microgliomatosis (PCNSL) was first described by the case report of Fisher *et al* ([@b52-ol-0-0-8839]) in 1969. Gross pathological sections of primary reticulum cell sarcoma of the brain (PCNSL) involved diffusely in the white matter were shown by Schaumburg *et al* ([@b53-ol-0-0-8839]) in 1972. The CT finding of a diffuse hypodense lesion without mass effect and contrast enhancement in widely infiltrating PCNSL that was proven pathologically by the brain biopsy was described by the case report of Tadmor *et al* ([@b54-ol-0-0-8839]) in 1978. MRI features of primary brain T-lymphoma presenting as progressive leukoencephalopathy were reported by the case report of Provinciali *et al* ([@b55-ol-0-0-8839]) in 1988, but it was not included in the present systematic review due to the lack of contrast-enhanced T~1~WI. The diffusely infiltrating PCNSL without formation of well-defined tumor masses was referred to as 'lymphomatosis cerebri' by the case report of Bakshi *et al* ([@b17-ol-0-0-8839]) in 1999, on the analogy of the term 'cerebral gliomas'. For a long time, the literature contained only case reports and small series regarding the clinical and radiological features of lymphomatosis cerebri. Moreover, the term 'lymphomatosis cerebri' has not been widely accepted, so the literature has a variety of descriptions for this diffusely infiltrating PCNSL. The recently published systematic review by Izquierdo *et al* ([@b48-ol-0-0-8839]) was the most detailed and the largest study on the clinical characteristics of 42 cases with lymphomatosis cerebri; however, the present systematic review focused on neuroradiological features of lymphomatosis cerebri using inclusion and exclusion criteria that differed from those used by Izquierdo *et al* ([@b48-ol-0-0-8839]). The present study defined lymphomatosis cerebri as a special entity with abnormal T2 hyperintensities that involved at least three cerebral lobes or three anatomical regions of the CNS, and where the non-enhancing lesions or the lesions without nodular or mass enhancement were identified on initial MR images. By contrast, the study by Izquierdo *et al* ([@b48-ol-0-0-8839]) represented lymphomatosis cerebri as the presence of diffuse white-matter disease in the brain MRI without contrast enhancement (although patchy contrast enhancement was also allowed).

The most common clinical presentation in the present systematic review was cognitive change or dementia (46.7%). Symptoms include persistent headache, seizures, nausea or vomiting, which all occur in other primary brain tumors ([@b56-ol-0-0-8839]), but appear less commonly in lymphomatosis cerebri. Lymphomatosis cerebri is observed most commonly in the aged adult, and tumor development appears to be unassociated with the immune status of the individuals. Conventional CSF analysis is non-specific. This indicates that lymphomatosis cerebri may rarely involve the leptomeninges. If CSF cytology and flow cytometry have negative results, definitive diagnostic methods should be considered rather than multiple lumbar punctures. With regard to the survival prognostic factors, the most recently published systematic review has suggested that Karnofsky Performance Status scores ≥70 and treatment with methotrexate are independently associated with a favorable outcome, whereas the type of T-cell lymphoma is an independent adverse prognostic factor in patients with lymphomatosis cerebri ([@b48-ol-0-0-8839]).

Diffuse abnormal T2 hyperintensity is one of the common characteristics of lymphomatosis cerebri. This abnormal T2-hyperintensity can involve the whole CNS, including the brain and spinal cord. A prominent feature of abnormal T2-hyperintensity is the involvement of the deep and periventricular white matter, and involvement of every lobe is reported. Subcortical white matter hyperintensity and U-fiber involvement are frequently observed. Corpus callosum and gray matter involvement are also apparent. The lesion distribution appears to have the propensity for diffuse infiltrative invasion throughout the CNS. It would be more precise if 'lymphomatosis cerebri' were renamed 'diffuse PCNSL' or 'diffuse lymphoma of the CNS'.

The spread of lesions along the corticospinal tract is another common characteristic of diffuse PCNSL based on the results in the present review. In 16 cases reporting follow-up MRI, extensions of lesions were clearly described, spreading along the corticospinal tract down from the cerebral white matter to the spinal cord. The case reported by Samani *et al* ([@b42-ol-0-0-8839]) is a representative example. The case reported by Chen and Dong ([@b46-ol-0-0-8839]) exhibited lesions spreading along the corticospinal tract in upwards and downwards directions at the same time. Lesions extending through the corpus callosum can also be found ([@b30-ol-0-0-8839],[@b42-ol-0-0-8839],[@b44-ol-0-0-8839],[@b46-ol-0-0-8839],[@b47-ol-0-0-8839]). The distribution and spread pattern of this diffuse abnormal signal mimics acute disseminated encephalomyelitis ([@b57-ol-0-0-8839]).

Contrast enhancement patterns of diffuse PCNSL on MR images could be divided into three forms: i) Non-enhancement; ii) various shapes of non-mass-like enhancement on initial MR images; and iii) single or multiple nodular or mass-like enhancement on the later follow-up MRI. Perivascular curvilinear enhancement in the present case appears to be first reported for diffuse infiltrative PCNL. Actually, this perivascular curvilinear enhancement was first described by Alsherbini *et al* ([@b58-ol-0-0-8839]) in 2014, in an immune-competent patient who presented with diffusely infiltrating PCNL involving the brainstem. In addition, 5 cases diagnosed definitively as PCNL presented as single or multiple nodular or mass-like enhancement with diffuse leukoencephalopathy on initial MR images, and then became diffusely infiltrating lesions on follow-up ([@b9-ol-0-0-8839],[@b55-ol-0-0-8839],[@b59-ol-0-0-8839]--[@b61-ol-0-0-8839]). Therefore, we speculate that these contrast enhancement patterns could occur at various stages during the development and progression of the disease, and that non-enhancement or non-mass-like enhancement on initial MRI may be only a special pattern of diffuse infiltrative PCNL.

On the basis of the aforementioned neuroimaging findings, similarly to gliomatosis cerebri ([@b5-ol-0-0-8839]), we hypothesize that diffuse PCNSL could be divided into primary and secondary subtypes, with primary subtypes exhibiting extensive CNS involvement at the time of initial clinical presentation, and secondary subtypes consisting of progressive infiltration of the brain by a typical locally infiltrative lymphoma observed on clinical follow-up over time. Primary subtypes could then be further divided into type 1 (classical form) and 2, with the classical form presenting as diffuse infiltration without a tumor mass at initial clinical presentation, and type 2 presenting as extensive CNS involvement and a tumor mass.

Radiological-pathological correlation of these contrast enhancement patterns in diffuse PCNSL has not previously been described in detail. It is generally recognized that the patterns and mechanisms of contrast-enhancement depend mostly on the permeability of the blood-brain barrier (BBB) and the extent of vascularity in CNS lesions ([@b62-ol-0-0-8839]), as well as tumor cellularity ([@b63-ol-0-0-8839]). The permeability of the BBB is the dominant factor in determining contrast enhancement patterns. The intact BBB will prevent the leakage of contrast material. In the regions with varying degrees of impairment of the BBB, the contrast agent will leak across the vessel wall and begin to accumulate in the perivascular interstitial fluid, which leads to interstitial (extravascular) enhancement ([@b62-ol-0-0-8839],[@b63-ol-0-0-8839]). The non-enhancement pattern is hypothesized to occur when tumor cells are diffusely infiltrative and have not resulted in significant disruption of the BBB ([@b13-ol-0-0-8839],[@b14-ol-0-0-8839],[@b16-ol-0-0-8839],[@b18-ol-0-0-8839],[@b20-ol-0-0-8839],[@b26-ol-0-0-8839],[@b30-ol-0-0-8839],[@b31-ol-0-0-8839]). Another possibility is the vanishing cancer phenomenon caused by corticosteroid-induced apoptosis and lymphoma cell lysis ([@b1-ol-0-0-8839],[@b22-ol-0-0-8839],[@b40-ol-0-0-8839]). The present systematic review highlights initial MR images, excluding corticosteroid effects from impacting the findings. Three patterns of neoplastic cell infiltration have been described as diffuse scattered infiltration, perivascular distribution and massive cluster. This could be hypothesized to explain the three contrast-enhancement patterns in diffuse PCNSL. However, in the present systematic review, a corresponding association was not found between contrast-enhancement patterns on neuroimaging and neoplastic cell infiltration patterns on pathology.

Cerebral punctate and curvilinear gadolinium enhancements with FLAIR hyperintensities in the corresponding areas indicate small vessel BBB disruption caused by a direct injury of the endothelial cell ([@b64-ol-0-0-8839]). Recent studies have shown that T1-weighted dynamic contrast-enhanced and dynamic susceptibility-weighted contrast-enhanced MRI could provide further information about intact microvascular integrity and neoangiogenesis, which can be used to improve the preoperative differentiation of PCNSL and other pathological conditions ([@b63-ol-0-0-8839],[@b65-ol-0-0-8839]).

DWI is useful in distinguishing between PCNSL and other tumors and tumor-mimicking lesions ([@b1-ol-0-0-8839],[@b2-ol-0-0-8839],[@b51-ol-0-0-8839],[@b57-ol-0-0-8839],[@b66-ol-0-0-8839],[@b67-ol-0-0-8839]). DWI findings in the present systematic review were isointense, slightly hyperintense and high hyperintense compared with normal gray matter. The extension of DWI hyperintensities corresponded with or without abnormal T2-hyperintensity. It is worth noting that almost all of the articles did not provide or describe ADC maps to distinguish between restricted diffusion and T2 shine-through effect on DWI, as well as cytotoxic and vasogenic edema. As for our present case, a combination of DWI and ADC hyperintense signal means vasogenic edema with T2 shine through effect. Therefore, the diagnostic value of DWI for diffuse PCNL should not be determined depending only on this available literature.

PET/CT is a well-established functional imaging method widely used in clinical neurooncology. In a review published by Kawai *et al* ([@b68-ol-0-0-8839]), it was concluded that PET/CT is useful in the diagnosis of typical PCNSL and can differentiate PCNSL from other malignant brain tumors. However, the value of PET/CT appears to be limited in the diagnosis of PCNSL with atypical radiological findings, including disseminated or non-enhancing lesions. PET findings in the present systematic review were varied and non-specific. This may be associated with regional cerebral metabolic rates of glucose, cellular differentiation, low cellularity and BBB integrity. The study by Kawai *et al* ([@b23-ol-0-0-8839],[@b69-ol-0-0-8839]) suggested that the parameters evaluated by FDG kinetic analysis may provide valuable information in the diagnosis of atypical PCNSL. For diffuse PCNSL, the usefulness of whole-body PET scan appears merely for the purposes of excluding systemic lymphoma ([@b2-ol-0-0-8839],[@b26-ol-0-0-8839],[@b29-ol-0-0-8839],[@b36-ol-0-0-8839],[@b66-ol-0-0-8839]).

Rapidly progressing dementia in the elderly and diffuse leukoencephalopathy on MRI should prompt the consideration of diffuse PCNSL. Although a substantial number of studies describe how to differentiate between rapidly progressing dementia in the elderly and diffuse leukoencephalopathy ([@b1-ol-0-0-8839]--[@b3-ol-0-0-8839],[@b26-ol-0-0-8839],[@b30-ol-0-0-8839],[@b33-ol-0-0-8839],[@b34-ol-0-0-8839],[@b36-ol-0-0-8839],[@b49-ol-0-0-8839],[@b51-ol-0-0-8839],[@b57-ol-0-0-8839],[@b62-ol-0-0-8839]--[@b71-ol-0-0-8839]), the diagnosis of diffuse PCNSL remains a challenge, and all cases in the present systematic review were misdiagnosed prior to brain biopsy or autopsy. The presumptive diagnosis of diffuse infiltrative brain neoplasia is proposed by the detailed analysis of medical history, clinical presentation, CSF results and serial MRI, including DWI and contrast enhancement. A decision to undertake a brain biopsy as soon as possible may benefit such patients.

The main limitations of the present systematic review are that only a few cases involved DTI ([@b29-ol-0-0-8839]), MRS ([@b29-ol-0-0-8839],[@b30-ol-0-0-8839],[@b49-ol-0-0-8839],[@b51-ol-0-0-8839]) or SPECT ([@b49-ol-0-0-8839]). The diagnostic values of these imaging methods have yet to be investigated in depth. Furthermore, the treatment and prognosis of lymphomatosis cerebri have not been analyzed in detail, as the present study focuses on describing the neuroradiological features of this condition.

In conclusion, although all data in the present systematic review are obtained from case reports, neuroradiological features of lymphomatosis cerebri could be characterized by rapidly progressing dementia in the elderly and diffuse leukoencephalopathy that tends to infiltrate the entire CNS along the corticospinal tract, possible involvement of gray matter, and a slight mass effect and varied contrast-enhancement patterns on MRI. It appears more reasonable to rename the so-called 'lymphomatosis cerebri' as 'diffuse PCNSL' or 'diffuse lymphoma of the CNS'. Non-enhancement or non-mass-like enhancement on MRI may only be a special form of diffuse PCNL during its development and progression. Early brain biopsy will minimize the duration of misdiagnosis in the setting of a presumptive diagnosis of diffuse infiltrative brain neoplasia.
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![CT findings of lymphomatosis cerebri from the present case report. (A-D) On February 25, 2015, the day of presentation to the neurological clinic, unenhanced CT showed (B) an abnormal low density in the right thalamus, external capsule and (C and D) parietal white matter. (E-H) On July 4, 2015, the follow-up unenhanced CT demonstrated abnormal hyperintensities that extended almost to all cerebral and cerebellar white matter, as well as the thalamus and brainstem. Multiple circular nodules were also observed in (E) the right cerebellar hemisphere, and (F and G) the bilateral occipital white matter and (H) right parietal white matter. CT, computed tomography.](ol-16-02-1463-g00){#f1-ol-0-0-8839}

![MRI findings of lymphomatosis cerebri from the present case report. (A-J) The initial MRI was performed on February 26, 2015. (A and F) FLAIR and (B and G) DWI showed diffuse multiple asymmetrical hyperintensity in (A) the bilateral basal ganglia and thalamus, (A, B and G) temporal white matter and (F and G) medial prefrontal cortex and periventricular white matter, as well as a slight mass effect on the posterior horn of the left lateral ventricle. (C and H) Apparent diffusion coefficient map showed mild hypotensity with no corresponding T2 hyperintensity, denoting a T2 shine-through effect and slight restricted diffusion. The lesions were (D and I) isointense on Tl-weighted spin-echo images, and (E and J) showed asymmetric perivascular curvilinear enhancement perpendicular to the lateral ventricle following gadolinium administration. (K-O) The follow-up MRI was performed on April 22, 2015. (K) FLAIR and (L) DWI demonstrated broader hyperintensity of the cerebral white matter. (O) The perivascular curvilinear enhancement on T~1~-weighted imaging with gadolinium expanded markedly. MRI, magnetic resonance imaging; FLAIR, fluid-attenuated inversion recovery; DWI, diffusion-weighted imaging.](ol-16-02-1463-g01){#f2-ol-0-0-8839}

![\[^18^F\]FDG-PET/CT findings of lymphomatosis cerebri from the present case report. On April 23, 2015, the PET/CT fusion images revealed inhomogeneous and patchy distribution of ^18^F-FDG uptake, with an SUVmax of 20.5 and SUVave of 15.3 in (A and B) the cerebrum, (C) brainstem, (C) cerebellum and (C and D) cervical cord. (D) No sign of systemic lymphoma was present. FDG, fluorodeoxyglucose; PET/CT, positron emission tomography/computed tomography; SUV, standardized uptake value.](ol-16-02-1463-g02){#f3-ol-0-0-8839}

![Pathological findings of lymphomatosis cerebri from the current case. On May 12, 2015, a stereotactic brain biopsy of the left frontal lobe revealed (A) prominent diffuse perivascular infiltrates of atypical large B-cells with irregularly shaped nuclei, (B) with strong staining for the B-cell marker CD-20 and for (C) Ki-67, indicative of highly proliferating cells. This case was assigned to the non-germinal center B-cell immunophenotype, as it was negative for (D) CD-10 and (E) Bcl-6, but positive for (F) MUM-1. (A) Hematoxylin and eosin, ×400 magnification; (B) anti-CD20, ×400 magnification; (C) anti-Ki-67, ×200 magnification; (D) anti-CD10, ×400 magnification; (E) anti-Bcl-6, ×400 magnification; and (F) anti-MUM-1, ×400 magnification. CD, cluster of differentiation; Bcl, B-cell lymphoma; MUM-1, multiple myeloma oncogene 1.](ol-16-02-1463-g03){#f4-ol-0-0-8839}

![Preferred reporting items of systematic reviews and meta-analyses-style flow diagram of the literature search for the systematic review. MRI, magnetic resonance imaging; CNS, central nervous system.](ol-16-02-1463-g04){#f5-ol-0-0-8839}

###### 

Summary of demographic and clinical features in 45 cases of lymphomatosis cerebri based on a systematic review.

  Characteristic                                                        Value
  --------------------------------------------------------------------- -----------
  Patients, n                                                           45
  Age, years                                                            
    Mean                                                                57.3
    Range                                                               28--85
  Sex, n (%)                                                            
    Male                                                                23 (51.1)
    Female                                                              22 (48.9)
  Clinical symptoms, n (%)                                              
    Cognitive changes/dementia                                          20 (44.4)
    Gait ataxia                                                         17 (37.8)
    Motor deficit                                                       16 (35.6)
    Sensory deficit                                                     5 (11.1)
    Language deficit                                                    11 (24.4)
    Visual problems                                                     5 (11.1)
    Memory loss                                                         11 (24.4)
    Personality changes                                                 8 (17.8)
    Seizures                                                            4 (8.9)
    Changes in consciousness                                            10 (22.2)
    Nausea or vomiting                                                  1 (2.2)
    Headache                                                            4 (8.9)
    Persistent fever                                                    2 (4.4)
  Immune status, n (%)                                                  
    Immunocompetent                                                     42 (93.3)
    Immunocompromised (AIDS patients)                                   3 (6.7)
  CSF examination^[a](#tfn1-ol-0-0-8839){ref-type="table-fn"}^, n (%)   
    Normal                                                              5 (14.3)
    Abnormal                                                            30 (85.7)
    Elevated protein                                                    22
    Increased cell counts                                               12
    Decreased glucose                                                   4
    Lymphocytosis                                                       1
    Atypical lymphocytes                                                1
  Pathology sampling, n (%)                                             
    Brain biopsy                                                        35 (77.8)
    Autopsy                                                             9 (20.0)
    Not mentioned                                                       1 (2.2)
  Results                                                               
    B-cell type                                                         40 (88.9)
    T-cell type                                                         4 (8.9)
    Unclassified                                                        1 (2.2)
  Outcome, months after symptom onset                                   
    Succumbed                                                           9.8
    Alive                                                               24

n=35. AIDS, acquired immunodeficiency syndrome; CSF, cerebrospinal fluid.

###### 

Summary of neuroimaging features in 45 cases of lymphomatosis cerebri based on a systematic review.

  Characteristic                           Value (%)
  ---------------------------------------- ---------------------------------
  MRI (Initial) Localization (n=45)        
  Cerebrum                                 
    Frontal lobe                           35 (77.8): Unilateral 8 (17.8),
                                           Bilateral 27 (60.0)
    Parietal lobe                          32 (73.3): Unilateral 6 (13.3),
                                           Bilateral 26 (57.8)
    Temporal lobe                          33 (73.4): Unilateral 7 (15.6),
                                           Bilateral 26 (57.8)
    Occipital lobe                         29 (64.4): Unilateral 5 (11.1),
                                           Bilateral 24 (53.3)
    Insular lobe                           26 (57.8): Unilateral 4 (8.9),
                                           Bilateral 22 (48.9)
    Periventricular                        10 (22.2): Unilateral 2 (4.4),
    white matter                           Bilateral 8 (17.8)
    Corpus callosum                        19 (42.2)
    Basal ganglia                          15 (33.3): Unilateral 1 (2.2),
                                           Bilateral 14 (31.1)
    Thalamus                               12 (26.7): Unilateral 4 (8.9),
                                           Bilateral 8 (17.8)
  Brainstem                                
    Midbrain                               21 (46.7): Unilateral 3 (6.7),
                                           Bilateral 18 (40.0)
    Pons                                   20 (44.5): Unilateral 3 (6.7),
                                           Bilateral 17 (37.8)
    Medulla                                14 (31.1): Unilateral 3 (6.7),
                                           Bilateral 11 (24.4)
    Cerebellum                             12 (26.6): Unilateral 1 (2.2),
                                           Bilateral 11 (24.4)
    Spinal cord                            5 (11.1)
  Signal                                   
  T~1~WI (n=13)                            
    Isointensity                           6 (46.2)
    Hypointensity                          7 (53.8)
    T2/FLAIR (n=45),                       45 (100.0)
    hyperintensity                         
  DWI (n=14)                               
    Isointensity                           2 (14.3)
    Slightly hyperintensity                11 (78.6)
    High hyperintense                      1 (7.1)
  Enhancement (n=45)                       
    Absence                                29 (64.4)
    Non-mass-like enhancement              16 (35.6)
    Subtle (faint/slight/little/minimal)   7 (43.8)
    Patchy                                 5 (31.2)
    Perivascular curvilinear               4 (25.0)
    Slight mass effect                     23 (51.1)
  MRS (n=4)                                
  N-acetylaspartate peak                   
    Normal                                 1 (25.0)
    Decreased                              3 (75.0)
  Choline peak                             
    Normal                                 1 (25.0)
    Increased                              3 (75.0)
    Myo-inositol peak, increased           1 (25.0)
    Lipid peak, increased                  1 (25.0)
    Creatine peak, normal                  1 (25.0)
  SPECT (n=1)                              
    Increased uptake                       1 (100.0)
  PET/CT (n=12)                            
    Increased uptake                       4 (33.3)
    Decreased uptake                       3 (25.0)
    Normal metabolism                      5 (41.7)

MRI, magnetic resonance imaging; T~1~WI, T~1~-weighted imaging; FLAIR, fluid-attenuated inversion recovery; DWI, diffusion-weighted imaging; MRS, magnetic resonance spectroscopy; SPECT, single-photon emission computed tomography; PET/CT, positron emission tomography/computed tomography.
